|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
CTG007114761 |
| 003 |
DE-627 |
| 005 |
20230425182334.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
210507s2022 xx |||||o 00| ||eng c |
| 035 |
|
|
|a (DE-627)CTG007114761
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2020-001154-22-ES
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)WA42380
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)2020-001154-22-DK
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 245 |
1 |
0 |
|a Tocilizumab plus background therapy versus placebo plus background therapy in patients with severe COVID-19 pneumonia.
|b A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA.
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 03-04-2020, Last updated: 2022-11-24
|
| 650 |
|
4 |
|a Medical Condition: Severe COVID-19 pneumonia MedDRA version: 21.1Level: PTClassification code 10035737Term: Pneumonia viralSystem Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
|
| 650 |
|
4 |
|a Study Type: Interventional
|
| 650 |
|
4 |
|a Phase: Phase 3
|
| 650 |
|
4 |
|a Recruitment Status: Not yet recruiting
|
| 650 |
|
4 |
|a 610
|
| 773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2022) vom: 19. Apr.
|
| 773 |
1 |
8 |
|g year:2022
|g day:19
|g month:04
|
| 856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001154-22
|z kostenfrei
|3 Volltext
|
| 912 |
|
|
|a GBV_CTG
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2022
|b 19
|c 04
|
Klinische Studie